# \[e-drug\] MSF and The Union release second edition of DR-TB drugs report

**URL:** <https://talk.edrugplus.org/t/e-drug-msf-and-the-union-release-second-edition-of-dr-tb-drugs-report/38136>\
**Category:** e-drug\
**Created:** [November 14, 2012, 9:57am UTC](https://talk.edrugplus.org/t/e-drug-msf-and-the-union-release-second-edition-of-dr-tb-drugs-report/38136 "2012-11-14T09:57:34Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Joanna\_KEENAN](https://avatars.discourse-cdn.com/v4/letter/j/96bed5/32.png) [@Joanna\_KEENAN](https://talk.edrugplus.org/u/Joanna_KEENAN)\
**Post date:** [November 14, 2012, 9:57am UTC](https://talk.edrugplus.org/t/e-drug-msf-and-the-union-release-second-edition-of-dr-tb-drugs-report/38136/1 "2012-11-14T09:57:34Z")

</div>

E-DRUG: MSF and The Union release second edition of DR-TB drugs report  
----------------------------------------------------------------------

Medecins Sans Frontieres and the International Union Against Tuberculosis and Lung Disease have today released the second edition of DR-TB Drugs Under the Microscope, a report examining prices, sources and issues surrounding medicines used for treatment of drug-resistant TB (DR-TB).

Download the report here:  
[http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition](http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition)  
[Please fix link in browser if broken]

With new, faster tools diagnosing more people than ever before, DR-TB is a growing epidemic, requiring an immediate response on how to address the urgent need for treatment scale up. But treatment scale up is hampered by a number of factors, including high prices (the average regimen costs US $4,000 - $6,000) and limited availability of quality-assured DR-TB medicines.

DR-TB Drugs Under the Microscope also looks at recent progress in the drug pipeline, with two completely new compounds - bedaquiline and delamanid - due for approval soon, the first new drugs in close to half a century. How these drugs will be used in treatment regimens - whether they’re added to existing regimes or news ones are devised - is critical in managing DR-TB treatment in the future. The report also looks at the issues surrounding access for DR-TB drugs, with a focus on linezolid and clofazimine.

The second edition of DR-TB Drugs Under the Microscope can be found here:  
[http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition](http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition)  
[Please fix link in browser if broken]

Joanna Keenan  
Press Officer  
Medecins Sans Frontieres - Access Campaign  
E: joanna.keenan[at]geneva.msf.org  
T: twitter.com/joanna\_keenan

msfaccess.org  
twitter.com/MSF\_access  
facebook.com/MSFaccess